the characteristics of patients at risk, among them patients with diabetes, hypertension, heart failure. Expanded to include sections on instrumental and laboratory diagnosis of coronavirus infection. All of these recommendations are addressed only to medical staff. They cannot apply on your own at home.
In particular, the recommendations stated that with thrombotic complications (deep vein thrombosis, pulmonary embolism and thrombosis of different localization), you should switch to therapeutic doses of anticoagulant agents. In patients with immune thrombocytopenia in history for the prevention and treatment of venous thromboembolic complications is recommended to use fondaparinux sodium. But low molecular weight heparins, and fondaparinux sodium is not recommended for use in patients with rapidly changing renal function.
the recommendations also indicate that the analysis of published data on clinical experience of managing patients with SARS-related coronaviruses SARS-CoV and MERSCoV, can provide some of the drugs recommended use in combination. These include chloroquine, hydroxychloroquine, lopinavir+ritonavir, azithromycin (in combination with gidroksihlorohina), preparations of interferons. Among drugs that are under clinical trials in patients with COVID-19, can be noted as umifenovir, ramdevpir, favipiravir.
“However, the available information on the results of therapy, these drugs do not allow a clear conclusion about their effectiveness or ineffectiveness, therefore it is permissible according to the decision of the medical Commission in the prescribed manner if the potential benefit to the patient exceeds the risk of their use”, – stated in the document.
Among the drugs promising for treatment of COVID-19, it should be noted group of antimalarial medicines: chloroquine, hydroxychloroquine, mefloquine. These drugs are used for therapy of malaria and other infections. In addition, in connection with anti-inflammatory and immunosuppressive effect of chloroquine and hydroxychloroquine has found its application in the treatment of patients with systemic connective tissue diseases, such as rheumatoid arthritis and lupus erythematosus. The mechanism of action of antimalarial drugs against some viral infections is not fully understood, the published data are observed several variants of their impact on COVID-19, which prevent the penetration of the virus into the cell.
it is Known that the most common clinical manifestation of new variant of coronavirus infection is bilateral pneumonia, in 3-4% of patients ZARregistrirana the development of acute respiratory distress syndrome (ARDS).
